

NCIC CLINICAL TRIALS GROUP - GI DISEASE SITE COMMITTEE

ESOPHAGOGASTRIC DISEASE ORIENTED GROUP

AGENDA

OPEN SESSION

Venue: Wren Room, Delta Chelsea Hotel, Toronto

Date: Saturday, April 30th, 2011

Time: 09:15 to 10:15 hrs

Chairs: Dr. Rebecca Wong & Dr. Christian Kollmansberger

| | | |
|---------------|---|-------------------------------------|
| 09:15 | WELCOME AND INTRODUCTION | DR. R. WONG & DR. C. KOLLMANSBERGER |
| 09:15 – 9:30 | COMPLETED TRIALS | |
| | GAC.1 (CALGB80101): PHASE III INTERGROUP TRIAL OF ADJUVANT CHEMORADIATION AFTER RESECTION OF GASTRIC OR GASTROESOPHAGEAL ADENOCARCINOMA | DR. G. BJARNSON |
| 09:30 – 10:00 | ONGOING TRIALS/CONCEPTS IN DEVELOPMENT | |
| | ES.2 (TROG 03.01): A RANDOMISED PHASE III STUDY IN ADVANCED OESOPHAGEAL CANCER TO COMPARE QUALITY OF LIFE AND PALLIATION OF DYSPHAGIA IN PATIENTS TREATED WITH RT VS CRT | DR. R. WONG |
| | TOP GEAR: A RANDOMISED PHASE III TRIAL OF PREOPERATIVE CHEMORADIOTHERAPY VERSUS PREOPERATIVE CHEMOTHERAPY FOR RESECTABLE GASTRIC CANCER | DR. T. LEONG |
| 10:00 – 10:15 | INTERGROUP TASK FORCE UPDATE | |
| | ONGOING TRIALS | |
| | RTOG 0436 - CRT +/- CETUXIMAB IN ESOPHAGEAL CA | |
| | RTOG1010 - TRASTUZUMAB IN HER2+ ESOPHAGEAL ADENOCARCINOMA | |
| | ACOSOG Z4051 – NEOADJ DOCETAXEL/CISPLATIN +/- PANITUMUMAB IN ESOPHAGEAL CA | |
| | E2208 – PHASE II RCT PACLITAXEL +/- IGF1R INHIBITOR | |
| | CALGB 80302 – PHASE II NEOADJ CPTII/CISPLATIN RT ESOPHAGEAL CA | |
| | TRIALS IN DEVELOPMENT/TO OPEN | |
| | CALGB/RTOG 80803: PHASE II RCT PET SCAN DIRECTED THERAPY IN ESOPHAGEAL CANCER | |
| | SWOG S0923: ERCC-1 DIRECTED THERAPY | |
| 10:15 | CLOSING REMARKS | |